3D Ultrasound Myocardial Mechanical Wave Measurements
3D Ultrasound Myocardial Mechanical Wave Measurements in Primary Mitral Regurgitation
Assistance Publique - Hôpitaux de Paris
40 participants
Oct 9, 2024
OBSERVATIONAL
Conditions
Summary
Primary mitral regurgitation (MR) is a frequent disease that can ultimately lead to heart failure. Primary MR represents the second most prevalent cause of cardiac valve surgery in high income countries. Progressive myocardial fibrosis due to chronic volume overload is recognized as a pathophysiological substrate of altered LV function in primary MR. As fibrosis leads to increased myocardial stiffness, ultrasound mechanical wave propagation measurements within the myocardium could provide important clinical information. Natural mechanical wave velocity (MWV) imaging, using High-frame-rate (HFR) echocardiography has emerged as a promising tool to evaluate myocardial stiffness. The objective is study is to evaluate the correlation between the LV myocardial stiffness (as assessed by 3D ultrasound myocardial MWV mapping) and myocardial interstitial fibrosis as measured using CMR (myocardial extracellular volume measure)
Eligibility
Inclusion Criteria3
- Severe primary MR patients (effective regurgitation orifice area ≥ 40mm²) with class I indication for surgery (symptoms and/or altered conventional parameters of LV function) (n=10 patients)
- Severe primary MR patients (effective regurgitation orifice area ≥ 40mm²) without class I indication of surgery (n=20 patients)
- Mild to moderate primary MR patients as defined by effective regurgitation orifice area ≥ 20mm² and < 40mm² (n=10 patients)
Exclusion Criteria7
- Permanent atrial fibrillation
- Acute primary severe MR
- Secondary MR
- Previous cardiac surgery of any kind
- Other severe left sided valvular disease
- Coronary artery disease
- Congenital cardiac disorder
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The participants are scanned with an ultrasound scanner
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06648577